Discovery and development of novel anti-cancer agents by targeting oncogenic transcription factors.

Research unit

INNOSUISSE

Project number

43016.1 IP-LS

Project title

Discovery and development of novel anti-cancer agents by targeting oncogenic transcription factors.

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Pharmaceuticals
Abstract (English)	Cellestia Biotech is a clinical stage company based in Basel, Switzerland. The company is developing first-in-class innovative anti-cancer therapies by targeting undruggable transcription factors (TFs). The aim of the study is to expand pipeline by designing and developing novel anti-cancer agents.